JPRN-jRCT2031200177已完成4 期
Post-marketing clinical trial of Pemafibrate in patients with impaired renal function
Ishibashi Shun0 个研究点目标入组 20 人开始时间: 2020年10月28日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Dyslidemia : Fasting Serum TG>=150mg/dL
- •2) Renal dysfunction (A:eGFR<30mL/min/1.73m^2, B:Hemodialysis, C:30<=eGFR<60mL/min/1.73m^2)
排除标准
- •1) Patients with severe liver damage, cirrhosis or biliary atresia patient
- •2) Patients with gallstones
- •3) Pregnant women or women who may be pregnant
- •4) Patients who have had a kidney transplant
研究者
相似试验
已完成
不适用
Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with untreated hypertriglyceridemiaHypertriglyceridemiaJPRN-UMIN000037026Sekino Hospital40
已完成
不适用
Prospective randomized trial on Pemafibrate versus omega-3-acid ethyl in patients with treated hypertriglyceridemiaHypertriglyceridemiaJPRN-UMIN000037110Sekino Hospital40
招募中
2 期
Randomized controlled trial of pemafibrate and fenofibrate for NAFLD with hypertriglyceridemiaJPRN-jRCTs031200280Iwaki Michihiro360
尚未招募
不适用
Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaprimary biliary cholangitisJPRN-UMIN000039350Shinshu University Faculty of Medicine, Department of Gastroenterology60
已完成
Unknown
A single-arm study of the efficacy of pemafibrate in patients with NAFLD (non-alcoholic fatty liver disease) complicated by dyslipidemiaAFLD (non-alcoholic fatty liver disease) complicated by dyslipidemiaJPRN-UMIN000049937ippon Medical School, gastroenterology, Hiroki Ono91